Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
16M
-
Shares change
-
+2.1M
-
Total reported value, excl. options
-
$165M
-
Value change
-
+$26.8M
-
Number of buys
-
28
-
Number of sells
-
-42
-
Price
-
$10.29
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q3 2018
76 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q3 2018.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16M shares
of 62.2M outstanding shares and own 25.78% of the company stock.
Largest 10 shareholders include FMR LLC (3.46M shares), BVF INC/IL (2.62M shares), FARALLON CAPITAL MANAGEMENT LLC (2.24M shares), MILLENNIUM MANAGEMENT LLC (1.03M shares), GREAT POINT PARTNERS LLC (982K shares), Pharmstandard International S.A. (751K shares), RENAISSANCE TECHNOLOGIES LLC (537K shares), Vanguard Group Inc (530K shares), DIMENSIONAL FUND ADVISORS LP (368K shares), and JENNISON ASSOCIATES LLC (350K shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.